Antitumor activity of specific immunotherapy with mucin containing CA 125 antigen in mice with CaO 1 ovarian carcinoma

• Published in: Bulletin of experimental biology and medicine Vol. 129; no. 4; pp. 383 - 385
• Main Authors: Amandzholov, B S, Sitdikova, S M, Lebedin, Y S, Chukanov, S V, Toptygin, A Y, Manzyuk, L V, Donenko, F V
• Format: Journal Article
• Language: English
• Published: United States Springer Nature B.V 01-04-2000
• Subjects: Animals; Antigen (tumor-associated); Antigenic determinants; Antigens; Antitumor activity; CA-125 Antigen - immunology; CA-125 Antigen - therapeutic use; Female; Humans; Immunoglobulin G; Immunoglobulin M; Immunotherapy; Life span; Mice; Mice, Inbred CBA; mucin; Mucins - immunology; Mucins - therapeutic use; Neoplasm Transplantation; Ovarian cancer; Ovarian carcinoma; Ovarian Neoplasms - immunology; Ovarian Neoplasms - therapy; Titration; Tumors
• ISSN: 0007-4888; 1573-8221
• DOI: 10.1007/BF02439278

Experiments in CBA mice with transplanted CaO 1 ovarian carcinoma possessing common antigenic determinants with human ovarian carcinoma showed that specific immunotherapy with mucin containing CA 125 antigen inhibited tumor growth by 60% and prolonged animal lifespan by 40-60% in comparison with the control. The correlation coefficient between the tumor size and antibody titer after injection of mucin was -0.4 for IgM and -0.6 for IgG. Titration of IgG may be used for monitoring of the efficiency of specific immunotherapy.